Haemonetics Co. (NYSE:HAE) EVP Josep Llorens Sells 987 Shares of Stock

Haemonetics Co. (NYSE:HAE) EVP Josep Llorens sold 987 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $95.08, for a total value of $93,843.96. Following the sale, the executive vice president now directly owns 21,310 shares of the company’s stock, valued at approximately $2,026,154.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Josep Llorens also recently made the following trade(s):

• On Friday, May 17th, Josep Llorens sold 822 shares of Haemonetics stock. The shares were sold at an average price of $94.82, for a total value of $77,942.04.

Haemonetics Stock Down 2.2 %

HAE opened at $93.20 on Wednesday. The company has a market capitalization of $4.73 billion, a PE ratio of 40.70, a price-to-earnings-growth ratio of 1.73 and a beta of 0.34. The firm has a 50-day simple moving average of $86.98 and a two-hundred day simple moving average of $83.38. The company has a quick ratio of 1.50, a current ratio of 2.56 and a debt-to-equity ratio of 0.83. Haemonetics Co. has a 52 week low of $70.74 and a 52 week high of $97.97.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.02. Haemonetics had a return on equity of 22.25% and a net margin of 8.98%. The company had revenue of $343.00 million during the quarter, compared to analyst estimates of $329.53 million. During the same period in the prior year, the company earned $0.77 earnings per share. The firm’s revenue was up 12.7% on a year-over-year basis. Analysts forecast that Haemonetics Co. will post 4.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Barrington Research upped their price target on shares of Haemonetics from $105.00 to $107.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. JMP Securities upped their target price on shares of Haemonetics from $115.00 to $125.00 and gave the stock a “market outperform” rating in a report on Friday, May 10th. TheStreet lowered Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Haemonetics in a research report on Friday, May 10th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, Haemonetics presently has an average rating of “Hold” and a consensus price target of $108.67.

Institutional Investors Weigh In On Haemonetics

Several large investors have recently bought and sold shares of the business. Capital Research Global Investors lifted its position in Haemonetics by 2.3% during the first quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier’s stock valued at $569,690,000 after purchasing an additional 151,183 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Haemonetics by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier’s stock valued at $462,293,000 after acquiring an additional 25,451 shares during the last quarter. Wellington Management Group LLP grew its position in Haemonetics by 3.2% in the fourth quarter. Wellington Management Group LLP now owns 3,268,083 shares of the medical instruments supplier’s stock worth $279,454,000 after acquiring an additional 101,029 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Haemonetics by 7.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 826,731 shares of the medical instruments supplier’s stock worth $70,697,000 after acquiring an additional 59,670 shares during the last quarter. Finally, Westfield Capital Management Co. LP raised its position in Haemonetics by 27.2% during the fourth quarter. Westfield Capital Management Co. LP now owns 712,061 shares of the medical instruments supplier’s stock valued at $60,888,000 after purchasing an additional 152,098 shares during the period. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.